Evidence map›Paper›PMID 32051719›Full record

ArticleArchives of medical science : AMS2020

Hepatitis B virus screening in patients with non-Hodgkin lymphoma in clinical practice in Poland - a report of the Polish Lymphoma Research Group.

Ewa Kalinka, Joanna Drozd-Sokołowska, Anna Waszczuk-Gajda, Joanna Barankiewicz, Elżbieta Zalewska, Igor Symonowicz, Ewa Lech-Marańda

Open access · goldAbstract read
In one paragraph

Article in Archives of medical science : AMS, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Ewa KalinkaDepartment of Oncology, Polish Mother's Memorial Hospital - Research Institute, Lodz, Poland.
Joanna Drozd-SokołowskaDepartment of Hematology, Oncology and Internal Diseases, Warsaw Medical University, Warsaw, Poland.
Anna Waszczuk-GajdaDepartment of Hematology, Oncology and Internal Diseases, Warsaw Medical University, Warsaw, Poland.
Joanna BarankiewiczDepartment of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
Elżbieta ZalewskaStatistical Methods Unit, University of Lodz, Lodz, Poland.
Igor SymonowiczDepartment of Oncology, Polish Mother's Memorial Hospital - Research Institute, Lodz, Poland.
Ewa Lech-MarańdaDepartment of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
Instytut Hematologii i Transfuzjologi · PLMedical University of Warsaw · PLPolish Mother’s Memorial Hospital Research Institute · PLUniversity of Łódź · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe risk of HBV reactivation is important in lymphoma patients receiving immunosuppressive chemotherapy containing steroids or anti-CD20 antibodies. We aimed to establish the prevalence of HBV Ag and anti-HBc serologic positive results in patients with non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) in Poland before anti-CD20 therapy initiation; to assess the frequency of insufficient HBV screening; and to assess the association between inadequate HBV screening and diagnosis according to the WHO classification and age or gender. MATERIAL AND

methodsWe retrospectively collected data from 805 patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia treated in 2016-2018.

resultsWe found a positive result of HBsAg in 13 (1.16%), and a negative result in 633 (78.64%) patients. The test was not done in 159 (19.75%) patients. In the HBsAg negative subgroup of 633 patients, we found that the anti-HBc was positive in 52 (8.22%), negative in 303 (47.87%) and not done in 278 patients. In 136 out of 805 (16.9%) patients diagnostics tests were not performed before therapy initiation. We found that age is significantly associated (

conclusionsIn Polish lymphoma patients the incidence of positive HBsAg and/or anti-HBc results is consistent with the prevalence in the United States or Australia. The adherence to appropriate HBV screening guidelines in Polish centers is not sufficient. We should intensify educational strategies in the global oncohematologic medical community.

Indexed as

anti-CD20 treatmentchronic lymphocytic leukemiahepatitis B virusnon-Hodgkin lymphomascreening

Identifiers

PMID32051719
PMCPMC6963131
OpenAlexW2969512253

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.